Cingulate Inc (CING) Price & Analysis

Compare

395 Followers

CING Stock Chart & Stats

$5.08

-$0.31(-6.60%)

At close: Jan 08 4:00 PM EST

$5.08

-$0.31(-6.60%)

Day’s Range― - ―

52-Week Range$3.20 - $6.01

Previous CloseN/A

Volume136.88K

Average Volume (3M)190.99K

Market Cap

$34.33M

Enterprise Value-$4.70B

Total Cash (Recent Filing)$6.12M

Total Debt (Recent Filing)$4.58M

Price to Earnings (P/E)―

Beta5.60

Next Earnings

Mar 06, 2026

EPS Estimate

-0.63

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.35

Shares Outstanding6,757,070

10 Day Avg. Volume270,731

30 Day Avg. Volume190,985

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)2.52

Price to Sales (P/S)0.00

P/FCF Ratio-1.01

Enterprise Value/Market Cap-137.02

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit8.12K

Enterprise Value/Ebitda218.91

Forecast

1Y Price Target

$27.33

Price Target Upside437.99% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Commercialization StrategyThe partnership with Indegene and hiring of an experienced Chief Commercial Officer support a focused pre-commercial ramp and reduce reliance on a large in-house sales force, lowering launch execution risk.

Product DifferentiationPrecision Timed Release (PTR) technology enables once-daily oral dosing with sustained efficacy and demonstrated fast onset, positioning CTx-1301 as a differentiated ADHD treatment amid ongoing stimulant shortages.

RegulatoryFDA acceptance of the NDA for CTx-1301 creates a clear regulatory pathway with potential approval and commercialization in mid-2026, which could unlock a new revenue stream if granted.

Bears Say

EarningsA reported net loss of $7.3 million and EPS of $(1.35) that missed internal and consensus estimates highlights profitability challenges and could weigh on investor sentiment.

GuidanceManagement's absence of forward guidance creates uncertainty around revenue and cash flow expectations, making it harder for investors to model future performance.

Cingulate Inc News

Cingulate continues stock-for-debt exchanges to reduce liabilities

Cingulate Inc ( ($CING) ) has shared an announcement. Between November 21, 2025 and January 2, 2026, Cingulate...

9d ago

CING

Cingulate Inc Reinstates Shane Schaffer as CEO

An announcement from Cingulate Inc ( ($CING) ) is now available. Cingulate Inc. announced that as of December...

27d ago

CING

Cingulate price target lowered to $16 from $17 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and...

2M ago

CING

Cingulate price target lowered to $16 from $17 at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and...

2M ago

CING

Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment

Cingulate Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from...

2M ago

CING

CING Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Cingulate, Inc. (CING) is scheduled to report 3rd quarter earnings on 11/17/2025. Regarding Q3 estimates, Wall Street analysts...

2M ago

CING

Cingulate Inc. Reports Q3 2025 Financial Results

Cingulate, Inc. ( ($CING) ) has released its Q3 earnings. Here is a breakdown of the information Cingulate,...

2M ago

CING

Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year

As of September 30, 2025, Cingulate (CING) had approximately $6.1 million in cash and cash equivalents, a $6.1...

2M ago

CING

Cingulate Inc Signs Note Purchase Agreement with Avondale

Cingulate Inc ( ($CING) ) just unveiled an announcement. On November 7, 2025, Cingulate Inc. entered into a...

2M ago

CING

Cingulate names Downey as CCO to lead launch prep for CTx-1301

Cingulate (CING) announced the appointment of Bryan Downey as Chief Commercial Officer, CCO, following the U.S. Food and...

2M ago

CING

Cingulate presents Phase 3 results for CTx-1301, met primary endpoint

Cingulate (CING) announced that the positive Phase 3 results from its pivotal trial of CTx-1301 in pediatric ADHD,...

3M ago

CING

Strategic Advancements and Partnerships Propel Cingulate Inc. Towards Market Success

Maxim Group analyst Naz Rahman reiterated a Buy rating on Cingulate Inc yesterday and set a price target...

3M ago

CING

Cingulate price target raised to $17 from $10 at Roth Capital

Roth Capital raised the firm’s price target on Cingulate (CING) to $17 from $10 and keeps a Buy...

3M ago

CING

Cingulate Inc’s NDA for CTx-1301 Accepted by FDA

Cingulate Inc ( ($CING) ) just unveiled an update. On October 14, 2025, Cingulate Inc. announced that the...

3M ago

CING

CING FAQ

What was Cingulate Inc’s price range in the past 12 months?

Cingulate Inc lowest stock price was $3.20 and its highest was $6.01 in the past 12 months.

What is Cingulate Inc’s market cap?

Cingulate Inc’s market cap is $34.33M.

When is Cingulate Inc’s upcoming earnings report date?

Cingulate Inc’s upcoming earnings report date is Mar 06, 2026 which is in 54 days.

How were Cingulate Inc’s earnings last quarter?

Cingulate Inc released its earnings results on Nov 13, 2025. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.47.

Is Cingulate Inc overvalued?

According to Wall Street analysts Cingulate Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cingulate Inc pay dividends?

Cingulate Inc does not currently pay dividends.

What is Cingulate Inc’s EPS estimate?

Cingulate Inc’s EPS estimate is -0.63.

How many shares outstanding does Cingulate Inc have?

Cingulate Inc has 6,757,070 shares outstanding.

What happened to Cingulate Inc’s price movement after its last earnings report?

Cingulate Inc reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -12.368%.

Which hedge fund is a major shareholder of Cingulate Inc?

Currently, no hedge funds are holding shares in CING

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cingulate Inc Stock Smart Score

Outperform

Fundamentals

Return on Equity

-284.50%

Trailing 12-Months

Asset Growth

162.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cingulate Inc

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Inc (CING) Earnings & Revenues

Historic Earnings Reports

CING Stock 12 Month Forecast

Average Price Target

$27.33

▲(437.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","59":"$59","16.25":"$16.25","30.5":"$30.5","44.75":"$44.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,16.25,30.5,44.75,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,7.803076923076923,11.986153846153847,16.16923076923077,20.352307692307694,24.53538461538462,28.71846153846154,32.90153846153846,37.08461538461538,41.26769230769231,45.45076923076923,49.63384615384615,53.816923076923075,{"y":58,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,5.443846153846154,7.2676923076923075,9.091538461538462,10.915384615384614,12.739230769230769,14.563076923076924,16.386923076923075,18.21076923076923,20.034615384615385,21.858461538461537,23.682307692307692,25.506153846153847,{"y":27.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.62,3.956923076923077,4.293846153846154,4.630769230769231,4.967692307692308,5.304615384615385,5.641538461538461,5.978461538461539,6.315384615384616,6.6523076923076925,6.989230769230769,7.326153846153846,7.663076923076924,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.85,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.93,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >